STF-118804 – 10 mg

Brand:
Cayman
CAS:
894187-61-2
Storage:
-20
UN-No:
Non-Hazardous - /

Nicotinamide phosphoribosyltransferase (Nampt) converts nicotinamide into nicotinamide mononucleotide (NMN), which is subsequently converted to NAD+ by NMN adenyltransferase. Cancer cells commonly have an unusually high rate of NAD+ turnover, suggesting that inhibition of Nampt might selectively target cancer cells. STF-118804 is a small molecule inhibitor of Nampt (IC50s = 3-6 nM) that prevents NAD+ synthesis from nicotinamide.{24585} It inhibits the viability of multiple B-cell acute lymphoblastic leukemia (B-ALL) cell lines with nanomolar potency and induces apoptosis in MV4-11 cells.{24585} At 50 mg/kg for 20 days, STF-118804 has been shown to improve survival in an orthotopic xenotransplant model of high-risk ALL in mice.{24585} It has also been shown to target leukemia stem cells.{24585}  

 

SKU: - Category:

Description

A Nampt inhibitor (IC50s = 3-6 nM) that prevents NAD+ synthesis from nicotinamide; inhibits the viability of multiple B-cell acute lymphoblastic leukemia cell lines with nanomolar potency and improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia in mice


Formal name: 4-[5-methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-N-(3-pyridinylmethyl)-benzamide

Synonyms: 

Molecular weight: 461.5

CAS: 894187-61-2

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Metabolism